<DOC>
	<DOCNO>NCT02125617</DOCNO>
	<brief_summary>The purpose study investigate cleavage product urokinase plasminogenactivator receptor ( uPAR ) plasma patient castration resistant prostate cancer predictive marker response abiraterone .</brief_summary>
	<brief_title>Urokinase Plasminogen Activator Receptor Abiraterone Treated Patients With Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Signed informed consent . Age ≥18 year male Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell histology Received least one two cytotoxic chemotherapy regimens metastatic CRPC . At least one regimen must contain taxane docetaxel . Prostate cancer progression assess investigator one following : PSA progression accord Prostate Cancer Working Group 2 ( PCWG2 ) criteria Solid Tumors ( RECIST ) criteria bone scan without PSA progression . Radiographic progression soft tissue accord Response Evaluation Criteria Ongoing androgen deprivation serum testosterone &lt; 2.0 nM Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 Platelet count ≥100,000/μL Serum albumin ≥30 g/dL Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) calculate creatinine clearance ≥ 60 mL/min Serum potassium ≥3.5 mmol/L Received abiraterone MDV3100 past . Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection . Abnormal liver function consist follow : Serum bilirubin ≥1.5 x ULN ( except subject document Gilbert 's disease , upper limit serum bilirubin 51 µmol/l ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥2.5 x ULN Uncontrolled hypertension ( systolic blood pressure ≥160 mmHg diastolic blood pressure ≥95 mmHg ) ; subject history hypertension allow provide blood pressure control antihypertensive therapy . Active symptomatic viral hepatitis chronic liver disease History pituitary adrenal dysfunction Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class III IV heart disease leave ventricular ejection fraction ( LVEF ) &lt; 50 % baseline . Known brain metastasis History gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug Any acute toxicity due prior chemotherapy radiotherapy resolve NCICTCAE ( Version 4.0 ) Grade ≤1 . Chemotherapy induce alopecia Grade 2 peripheral neuropathy allow . Use anticancer therapy include cytotoxic , radionucleotide , immunotherapy ; diethylstilbestrol ; PCSPES ; spironolactone ( ie , ALDACTONE , SPIRONOL ) ; preparation saw palmetto thought endocrine effect prostate cancer , within 4 week Cycle 1 Day 1 Prior systemic treatment azole drug ( eg , fluconazole , itraconazole , ketoconazole ) within 4 week Cycle 1 Day 1 Current enrolment investigational drug device study participation study within 30 day Day 1 Condition situation , investigator 's opinion , may put subject significant risk , may confound study result , may interfere significantly subject 's participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Urokinase Plasminogen Activator Receptor</keyword>
	<keyword>Plasma</keyword>
	<keyword>Predictive marker</keyword>
</DOC>